Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
Web
NewsPlease enter a web search for web results.
News
WebPTC to acquire Sangamo's gene therapy for Fabry disease
9+ hour, 52+ min ago (613+ words) Company to seek FDA accelerated approval of one-time therapy Written by Steve Bryson, PhD | Aug. 27, 2026 PTC Therapeutics has been selected as the winning bidder to acquire ST-920 (isaralgagene civaparvovec), a one-time gene therapy candidate for Fabry disease, from the therapy’s…...
Genezen to Offer Access to 4basebio Synthetic DNA Platform for Viral Vectors
4+ hour, 43+ min ago (217+ words) Drug developers will be able to use 4basebio’s research use only, high-quality, GMP-grade development and clinical programs. Editor’s Take: A cell-free approach to manufacturing can shorten DNA production timelines compared to traditional plasmid manufacturing. Genezen is offering drug developers access…...
Rayzebio to invest $173 million in Indiana for new Whitestown cancer therapy plant
12+ hour, 20+ min ago (216+ words) INDIANAPOLIS — RayzeBio, a Bristol Myers Squibb company, plans to invest more than $173 million in its central Indiana operations and build a new facility in Whitestown. The company announced plans to establish an approximately 450,000-square-foot facility at the Anson Industrial Park…...
Galen and POA Pharma launch Galsana, a new global brand for rare metabolic diseases
8+ hour, 21+ min ago (216+ words) The Pharma Letter - Galen and POA Pharma launch Galsana, a new global brand for rare metabolic diseases Northern Ireland-headquartered pharma company Galen has unveiled Galsana, a new global brand uniting its metabolic disease portfolio with that of Copenhagen-based POA Pharma,…...
AlphaValue/Baader Europe Upgrades Novonesis to Add After Q2 Beat
12+ hour, 59+ min ago (37+ words) marketscreener.com Published on 08/27/2026 at 07:34 am EDT Novonesis: Strong Q2 beat: Guidance raised; buyback announced August 26, 2026 at 12:40 pm EDT...
Policies can unlock medicinal plant biotech innovation
14+ hour, 13+ min ago (112+ words) University World News University World News - University World News - Do not process my personal data. If you wish to opt-out of the processing of your personal data please use the below opt-out section to confirm your selection. Please note that…...
SK Biopharmaceuticals Pays Up to $795 Million for Next-Generation Epilepsy Drug
22+ hour, 33+ min ago (475+ words) Seoul Economic Daily...
Expert tips for launching pharma products in Europe
1+ day, 1+ hour ago (531+ words) An industry expert shares important tips with the Pharma Conversation Podcast about how best to approach a product launch in Europe. Launching a pharmaceutical product in Europe is one of the most strategically significant and operationally complex moves a biotech…...
UMB Celebrates America at 250: UMSOP Innovators Helped Build the Nation’s Pharmaceutical Industry - The Elm
1+ day, 1+ hour ago (535+ words) Nine “Founding Pharmapreneurs” delivered groundbreaking advances in science, medicine, and innovation, solidifying the School of Pharmacy’s global reputation as a leader in the field. The United States is commemorating the 250th anniversary of the Declaration of Independence in 2026, but the celebration…...
DARE: New product launches and key clinical milestones drive a pivotal growth phase
1+ day, 3+ hour ago (72+ words) TradingView DARE: New product launches and key clinical milestones drive a pivotal growth phase A pivotal period is underway with new product launches, including Flora Sync LF5 and DARE to PLAY, and major clinical milestones expected next year for Ovaprene and…...